Clewell H J
K.S. Crump Division, ICF Kaiser International, Ruston, LA, USA.
Toxicol Lett. 1995 Sep;79(1-3):207-17. doi: 10.1016/0378-4274(95)03372-r.
Physiologically based pharmacokinetic (PBPK) modeling is an important tool for improving the accuracy of human health risk assessments for hazardous substances in the environment. The proper use of PBPK modeling can reduce uncertainties that currently exist in risk assessment procedures by providing more scientifically credible extrapolations across species and routes of exposure, and from high experimental doses to potential environmental exposures. Current applications of PBPK models range from relatively straightforward uses for the extrapolation of chemical kinetics across species, route, and duration of exposure to much more demanding chemical risk assessment applications requiring a description of complex pharmacodynamic phenomena such as mitogenicity and hyperplasia secondary to cytotoxicity. PBPK modeling helps to identify the factors that are most important in determining the health risks associated with exposure to a chemical, and provides a means for estimating the impact of those factors both on the average risk to a population and on the specific risk to an individual. The chief challenge in the application of PBPK modeling in human health risk assessment lies in the need to generate chemical-specific data to support the development and validation of the models. Extensive use of rapidly developing in vitro and structure-activity relationship techniques is needed to provide the data required for the large number of hazardous chemicals currently contaminating the environment.
基于生理的药代动力学(PBPK)模型是提高环境中有害物质人体健康风险评估准确性的重要工具。正确使用PBPK模型可以通过提供跨物种、暴露途径以及从高实验剂量到潜在环境暴露的更具科学可信度的外推,减少当前风险评估程序中存在的不确定性。PBPK模型目前的应用范围较广,从相对简单的用于跨物种、暴露途径和暴露持续时间的化学动力学外推,到更具挑战性的化学风险评估应用,后者需要描述复杂的药效学现象,如细胞毒性继发的有丝分裂原性和增生。PBPK模型有助于确定在决定与接触化学物质相关的健康风险方面最重要的因素,并提供一种方法来估计这些因素对人群平均风险和个体特定风险的影响。在人体健康风险评估中应用PBPK模型的主要挑战在于需要生成特定化学物质的数据,以支持模型的开发和验证。需要广泛使用快速发展的体外和构效关系技术,以提供大量目前污染环境的有害化学物质所需的数据。